$22.71
-0.08-0.35%
Last update: Nov 10, 4:27 PM
uniQure NV
QURENASDAQ
uniQure fell 12.8% from $26.15 to $22.79, behind the S&P 500's +10.0%. Its worst day was Sep 29 (−37.3%), and its low came Mar 3 at $9.03.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.38 missed the $-0.79 estimate on $3.7M revenue (est. $5.4M).
0.0% · S&P 500 +1.6%
EPS of $-0.56 beat the $-0.85 estimate on $5.6M revenue (est. $5.7M).
Story events cover the past 12 months · Times ET
−32.8% · S&P 500 +0.1%
EPS of $-0.85 missed the $-0.78 estimate on $3.6M revenue (est. $5.0M).
+2.3% · S&P 500 +0.8%
uniQure shares rose 78.4%, while the S&P 500 fell 1.5%.
+78.4%, the year's best day · S&P 500 −1.5%
EPS of $-1.22 missed the $-0.75 estimate on $5.8M revenue (est. $5.2M).
+9.3% · S&P 500 −1.5%
uniQure closed at its highest level of the year, 95.2% above where the year started.
+7.6% · S&P 500 +0.3%
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of
−37.3%, the year's worst day, on 30M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.88 missed the $-0.82 estimate on $5.2M revenue (est. $5.8M).
−3.5% · S&P 500 +1.7%
Where it ended: a close of $22.79 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $-0.77, revenue est. $6.1M).
Nothing in the past 12 months.
All QURE dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for QURE and SPY from Benzinga historical bars. Not investment advice.
